MCL1 and plasma cell myeloma: As a mono-therapeutic, Venetoclax has also been reported to be effective against other lymphomas with high Bcl-2 expression levels, as in MCL, myeloma, refractory AML [444], follicular lymphoma and some diffuse large B-cell lymphomas [446], whereby the dose administered could be correlated with expression levels of Mcl1 and Bcl-xL [447].